AU2008300612B2 - Production of leaf extracts of Pittosporum phillyraeoides and the use thereof in medicine - Google Patents
Production of leaf extracts of Pittosporum phillyraeoides and the use thereof in medicine Download PDFInfo
- Publication number
- AU2008300612B2 AU2008300612B2 AU2008300612A AU2008300612A AU2008300612B2 AU 2008300612 B2 AU2008300612 B2 AU 2008300612B2 AU 2008300612 A AU2008300612 A AU 2008300612A AU 2008300612 A AU2008300612 A AU 2008300612A AU 2008300612 B2 AU2008300612 B2 AU 2008300612B2
- Authority
- AU
- Australia
- Prior art keywords
- extract
- leaves
- pittosporum
- phillyraeoides
- extract according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 46
- 241001315608 Pittosporum angustifolium Species 0.000 title claims description 12
- 239000003814 drug Substances 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 5
- 102000013142 Amylases Human genes 0.000 claims description 3
- 108010065511 Amylases Proteins 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 239000004382 Amylase Substances 0.000 claims description 2
- 235000019418 amylase Nutrition 0.000 claims description 2
- 239000007920 enema Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 241001092090 Pittosporum Species 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 241000218228 Humulus Species 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001315611 Pittosporum ligustrifolium Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 240000004429 Tephrosia purpurea Species 0.000 description 1
- 235000017517 Tephrosia purpurea Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930189514 ganomycin Natural products 0.000 description 1
- 229930184727 ginkgolide Natural products 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
An extract made of leaves of
Description
Application No. PCT/EP2008/062239 SMB Publication No. W02009/037225 Preparation of Leaf Extracts from Pittosporum philyraeoides and the Use Thereof in Medicine The present invention relates to extracts from leaves of a subspecies of the tree or shrub Pittosporum phillyraeoides, especially Pittosporum phillyraeoides DC, subspecies microcarpa S. Moore, methods for the preparation thereof, and the use of the extracts themselves or of pharmaceutical composition containing them for prophylactic and therapeutic uses, especially in malignant diseases. Plants and their components, such as leaves, bark, flowers, seeds, fruits and roots, are still an important source of medically utilizable defined substances or also undefined mixtures of substances. On a worldwide or regionally limited basis, original or chemically modified natural substances are used as medicines. The field of indications ranges from the treatment of chronic and acute inflammations, infections, circulatory disorders to cancers. Examples of pharmacologically active substances of plant origin include hydrolases, such as bromelain and papain, ganomycins, ginkgolides and taxol. The medically utilized active substances from plants can be processed in various forms. They range from aqueous extracts prepared from dried plant parts to elaborately isolated active substances, which may be chemically modified in addition. The chemical processes employed for this purpose are determined by the chemical or physicochemical properties of the active substances or groups of substances. A mechanical and optionally enzymatic pretreatment is usually effected to digest the plant components. Microwaves or ultrasound have also become commonly H:\rbr\InLerwoven\NRPortbl\DCC\RBR\4951960_1.doc-01.03.2013 -2 used means in the meantime. All these processes may also be employed in combination. In the extraction of plant components, a processing method that saves the active substances as much as possible is sought while ineffective or disturbing substances should be depleted. With leaves of Pittosporum phillyraeoides, this object is achieved, in particular, by the use of aqueous and/or alcoholic solvents. Aqueous and organic solvents of different polarities, ion concentrations and temperatures are usually employed for the extraction. Mixtures of different solvents are also common, as are different extraction times, for example, by using Soxhlet extractors. The extractions, scheduled, for several hours, are frequently supported by using agitation apparatus. Largely independently of the extraction methods employed, the end of this process involves the removal of organic solvents, the concentration of the extract and possibly its freeze-drying. Possible oral dosage forms of the extracts obtained are drops, capsules, coated tablets or tablets, optionally in enteric design. Ointments, suspensions or sprays prepared for topical application are further commonly used. Plant extracts can also be employed therapeutically as injectable liquids (intravenously, intraperitoneally, intramuscularly, intratumorally). Additions of auxiliaries that improve the solubility of the extracts, their stability and bioavailability are commonly used. In one aspect, the present invention provides processes for the preparation of extracts from the leaves of Pittosporum phillyraeoides DC, subspecies microcarpa S. Moore, and the use thereof, also in pharmaceutical formulation, for the prophylaxis and treatment of malignant diseases. Surprisingly, it has been found that particularly processed forms of the leaf extracts have a H:\ayl\Interwoven\NRPortbl\DCC\AYL\4951968_1.doc-01.03.2013 -3 particular medicinal effect on cancers, such as prostate cancer, lung cancer or breast cancer. Several synonyms of Pittosporum phillyraeoides are known, for example, P. ligustrifolium, longifolium, salicinum and lanceolatum. The plant is endemic in Australia, among others, where is bears a number of trivial names, such as willow tree, gumbi gumbi, butter bush, weeping Pittosporum. Outside Australia, the evergreen trees or shrubs of the genus Pittosporum are used by humans in tropical climates worldwide, for example, as ornamental plants, fish poison or hop substitute. Their application for medicinal purposes is known from the aborigines. Thus, the leaves are mechanically crushed by the medicine women by chewing and fermented by the saliva. The leaf pulp admixed with saliva is subsequently collected and warmed up by exposure to the sun. The leaf pulp is orally administered to sick people or applied to wounds or painful body parts. The preparation of a tea from the leaves of Pittosporum philyraeoides is also common is some regions. The leaf extracts can be prepared by various methods known from phytopharmacy. The following aqueous, enzymatic or alcoholic extraction methods have been found useful for the production of extracts from leaves of Pittosporum phillyraeoides DC, subspecies microcarpa S. Moore. Thus, the invention relates to an extract from leaves of Pittosporum phillyraeoides DC, especially var. microcarpa S. Moore. The leaves may have various ages and also various degrees of dryness. Accordingly, the present invention provides an extract from leaves of Pittosporum phillyraeoides DC, prepared by a process comprising extracting the leaves with a solvent from the group consisting of water, methanol, ethanol and combinations thereof, at a temperature in the range of from 10 to 80 *C and fermenting the leaves and solvent to provide an extract.
H:\rbr\Interwoven\NRPortbl\DCC\RBR\4951968_1.doc-01.03.2013 -4 The extract according to the invention is obtainable by extraction with water, methanol, ethanol or combinations thereof, optionally with the addition of amylase. The extract is typically obtained by treatment with the mentioned extractants water, methanol and/or ethanol at elevated temperatures. Extractions at temperatures up to the boiling point of the respectively employed alcoholic extractant, or up to 80 *C for water, have proven to be particularly useful. However, temperature ranges of from 10 *C to 80 *C are typically used. After the liquid extract has been obtained, it can be solidified by evaporating the solvent, especially by freeze-drying. According to the invention, the extract can be administered in a pharmaceutical formulation for oral and extracorporeal topical administration and for intravenous, intramuscular or intracutaneous application and for application as a clysma. The extract according to the invention is useful for the prophylaxis and therapy of malignant diseases. For the preparation of an extract according to the invention for administration, stabilizing pharmaceutical, chemical or biological auxiliaries may be added to the extract. The extract may also be administered in combination with other pharmacologically or medicinally active substances or mixtures of substances. The invention also relates to the use of the extract according to the invention for the treatment of malignant diseases. Example 1: Preparation of the extract by aqueous decoction for several weeks at varying temperatures (10 to 80 *C) The dried and shredded leaves are mixed with sterile tap water at a ratio of 800 to 1200 g per liter of water, and heated at 70 ± 10 *C for about one hour. The use of fermentation tanks having a volume of about 10-20 I of liquid is H.\rbr\Interwoven\NRPortbl\DCC\RBR\4951968_1.doc-01.03.2013 -5 advantageous. The fermentation tank filled with the mixture is exposed to the natural temperature variations in the open air for 2-3. At the north Australian east coast, the temperature vary from 15 to 40 *C. Thereafter, the thus formed extract is filtered and admixed with alcohol (final concentration 15 ± 5%). The extract is again passed through a wine filter and then stored at 4 *C until use within 12 months. Example 2: Preparation of the extract by enzymatic digestion by means of amylase Amylase of commercial origin is added to physiological saline at a suitable concentration at a ratio of 20 : 80 (grams : volume) and incubated with shaking for 1 to 24 hours or several days, the temperature being 37 *C for 1 hour and thereafter room temperature (20 ± 4 *C). Subsequently, the liquid was filtered, and the filtrate was reduced in volume by lyophilization. Example 3: Preparation of the extract by hot ethanol The extract is obtained by ethanol at 70 *C, which is incubated at a mixing ratio of 1 : 10 (grams of shredded leaves : ml of ethanol) with shaking for 24 hours. After the filtration, the ethanol is distilled off to leave the extract as a residue. Example 4: Preparation of the extract by a methanol/water mixture The composition of the extraction mixture is similar to that of Example 3, wherein a mixture of 80% methanol with water serves as the extractant. The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
H:\rbr\lnteoven\NRPortbl\DCC\RBR\4951968_1.dc-O1.03.2013 -6 Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. References Cooper, R. C. : The Australian and New Zealand species of Pittosporum, Annals of the Missouri Botanical Garden 1956, vol. 43, no. 2, pp87-188 H~nsel R. and 0. Stricher: Pharmakognosie Phytopharmazie, 2004, Springer Verlag Berlin Webb, L.J.: The use of plant medicines and poisons by Australian Aborigines, Mankind 1969, vol. 7, pp137-146
Claims (11)
1. An extract from leaves of Pittosporum phillyraeoides DC, prepared by a process comprising extracting the leaves with a solvent selected from the group consisting of water, methanol, ethanol and combinations thereof, at a temperature in the range of from 10 to 80 *C and fermenting the leaves and solvent to provide an extract.
2. The extract of claim 1 further comprising adding amylase to the leaves and solvent prior to fermentation.
3. The extract of claims 1 or 2 wherein the process further comprises lyophilizing the extract.
4. The extract of any one of claims 1 to 3 wherein the leaves are Pittosporum phillyraeoides var. microcarpa leaves.
5. The extract according to any one of claims 1 to 4 further comprising stabilizing pharmaceutical, chemical or biological auxiliaries.
6. The extract according to any one of claims 1 to 5 further comprising at least one other pharmacologically or medicinally active substance or mixtures of substances.
7. Use of an extract according to any one of claims 1 to 6 in the preparation of a medicament for oral administration; extracorporeal topical administration; intravenous, intramuscular or intracutaneous application; or for application as a clysma.
8. Use of an extract according to any one of claims 1 to 6 for the prophylaxis or treatment of malignant diseases.
9. A medicament comprising the extract of any one of claims 1 to 6. H:\rbr\Interwoven\NRPortbl\DCC\RBR\4951968_1.do -01.03.2013 -8 9. A medicament comprising the extract of any one of claims 1 to 6.
10. A method of treating a malignant disease comprising administering to a person in need thereof a therapeutically effective amount of an extract according to any one of claims 1 to 6.
11. An extract according to claim 1 substantially as hereinbefore described with reference to any one of the Examples.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007044094A DE102007044094A1 (en) | 2007-09-14 | 2007-09-14 | Production of leaf extracts of Pittosporum phillyraeoides and their use in medicine |
| DE102007044094.6 | 2007-09-14 | ||
| PCT/EP2008/062239 WO2009037225A2 (en) | 2007-09-14 | 2008-09-15 | Production of leaf extracts of pittosporum phillyraeoides and the use thereof in medicine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2008300612A1 AU2008300612A1 (en) | 2009-03-26 |
| AU2008300612B2 true AU2008300612B2 (en) | 2013-03-28 |
| AU2008300612C1 AU2008300612C1 (en) | 2024-10-03 |
Family
ID=40384057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008300612A Active AU2008300612C1 (en) | 2007-09-14 | 2008-09-15 | Production of leaf extracts of Pittosporum phillyraeoides and the use thereof in medicine |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2008300612C1 (en) |
| DE (1) | DE102007044094A1 (en) |
| WO (1) | WO2009037225A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102604418B (en) * | 2012-01-19 | 2013-11-13 | 常州美胜生物材料有限公司 | Extraction, separation and dyeing application of natural dye |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060122129A1 (en) * | 2003-10-09 | 2006-06-08 | Chan Pui-Kwong | Composition comprising triterpene saponins and compounds with angeloyl functional group, methods for preparing same and uses thereof |
-
2007
- 2007-09-14 DE DE102007044094A patent/DE102007044094A1/en not_active Ceased
-
2008
- 2008-09-15 AU AU2008300612A patent/AU2008300612C1/en active Active
- 2008-09-15 WO PCT/EP2008/062239 patent/WO2009037225A2/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060122129A1 (en) * | 2003-10-09 | 2006-06-08 | Chan Pui-Kwong | Composition comprising triterpene saponins and compounds with angeloyl functional group, methods for preparing same and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009037225A2 (en) | 2009-03-26 |
| DE102007044094A1 (en) | 2009-04-02 |
| AU2008300612A1 (en) | 2009-03-26 |
| AU2008300612C1 (en) | 2024-10-03 |
| WO2009037225A3 (en) | 2009-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Akinpelu et al. | Anacardium occidentale | |
| Panchawat | Ficus religiosa Linn.(Peepal): A Phyto-Pharmacological | |
| KR20090034401A (en) | Eucalyptus extract, method of preparation and therapeutic uses thereof | |
| JP2009542634A (en) | Pharmaceutical composition for the prevention and treatment of inflammatory diseases comprising extract | |
| KR20130078052A (en) | Antibacterial compositions containing plant extracts or fractions thereof under light intensity | |
| KR101930264B1 (en) | Cosmetic composition for inhibiting secretion of sebum and for improving acne symptoms containing natural complex extract | |
| Akash et al. | Tinospora cordifolia, A Reservoir plant for Therapeutic applications: A Review | |
| Ugbabe et al. | Preliminary phytochemical, antimicrobial and acute toxicity studies of the stem, bark and the leaves of a cultivated Syzygium cumini Linn.(Family: Myrtaceae) in Nigeria | |
| KR101182824B1 (en) | Composition having anti-allergic activity containing Zanthoxylum piperitum DC fruit extract or glycoprotein isolated from its extract | |
| Raisagar et al. | Comparative study of wound healing effect of bark extracts of Ficus religiosa & Ficus benghalensis by mice model | |
| KR102181220B1 (en) | Pharmaceutical composition for anti-cancer containing medicinal gerb extracts | |
| CN100335073C (en) | Process for preparing semen momordicae seed extract containing triterpene saponin component | |
| AU2008300612B2 (en) | Production of leaf extracts of Pittosporum phillyraeoides and the use thereof in medicine | |
| JP5854674B2 (en) | Dipeptidyl peptidase IV inhibitor | |
| JP2010516755A (en) | Pharmaceutical composition for prevention and / or treatment of inflammatory diseases, comprising a mixed extract of Tsukiishi wisteria and Ichiyakuso | |
| KR20190119020A (en) | A composition for anti-inflammation comprising hemistepta lyrata extract | |
| RU2665968C1 (en) | Method for obtaining an agent of choleretic, anti-inflammatory and antioxidant activity | |
| RU2402344C1 (en) | METHOD FOR PREPARING PHYTOPREPARATIONS OF SOME SPECIES OF HEDYSARUM (Hedysarum theinum, Hedysarum neglectum) | |
| JP5896618B2 (en) | Melanin production inhibitor | |
| RU2303993C1 (en) | Treatment and prophylaxis means applicable for treating young agricultural animals and method for preventing and treating calves for gastrointestinal tract diseases | |
| JP4979053B2 (en) | Anticancer agent containing gentian extract, health supplement and medicinal cosmetic, and method for producing gentian extract | |
| Abdelrahman | Hepatoprotective activity of ethanolic and ethyl acetate extracts of Sterculia Setigera against carbon tetrachloride induced hepatotoxicity in albino rats | |
| CN103083376B (en) | Can be used for the Rhizoma Ligustici extract for the treatment of rhinitis | |
| RU2174009C1 (en) | Balsam "shishechka" possessing tonic and antiinflammatory action | |
| KR100552991B1 (en) | Extraction and Purification of Active Active Ingredients from Jinkyo and Herbal Medicine Compositions Containing the Extracts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: ADD CO-INVENTOR AMATO, KATJA |
|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ VON GLISZCZYNSKI, KLAUS-OTTO AND AMATO, KATJA; KUNZE . |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ VON GLISZCZYNSKI, KLAUS-OTTO AND AMATO, KATJA |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 APR 2024 |